Report interim open-label data for EPP/XLP BEACON trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Aug 2022
- Due
- 30 Jun 2023
- Delivered
- 9 Jun 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Interim open-label data expected by 1H’23”
What we found
Evidence strength A What the grades mean
Disc Medicine presented interim open-label BEACON trial data for EPP/XLP on June 9, 2023, within the 1H'23 deadline.
-
A SEC Filing
“In July 2022, Disc initiated BEACON, a Phase 2 open-label, parallel-dose clinical trial of bitopertin in EPP and XLP patients that is being conducted at sites in Australia. Interim data are expected in the first half of 2023.” ✓ confirmed on the page
-
B Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
“Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, today presented preliminary findings from its ongoing, Phase 2 open-label BEACON trial”
-
D Interim Analyses from the Beacon Trial: A Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria
“The trial is ongoing and these data reflect initial data from 15 subjects enrolled as of the data cutoff of May 8, 2023”
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Interim open-label data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-IRON-002111 · Corrections policy